Faculty

Institution

Unit

Venue

Parijatham Thomas

Associate Professor

The University of Texas MD Anderson Cancer Center

Affiliations

Department Of Clinical Cancer Prevention, 1515 Holcombe Blvd. Unit 1360

Department Of Clinical Effectiveness

Division Of Cancer Prevention And Population Sciences

The University of Texas MD Anderson Cancer Center

Parijatham Thomas is currently serving as a Clinical Cancer Prevention, 1515 Holcombe Blvd. Unit 1360 Associate Professor at The University of Texas Md Anderson Cancer Center.

Honors

Create free account to unlock more features

Experiences

Create free account to unlock more features

Education

Create free account to unlock more features

Parijatham Thomas

The University of Texas MD Anderson Cancer Center

Associate Professor

You can click a keyword to filter the displayed items

breast cancer oncology pharmacology breast oncology health sciences cancer care high risk surgical oncology preventive medicine randomized presurgical trial health policy preventive healthcare health care cancer disparities cancer prevention breast surgery pathology survival analysis diagnosis risk management cancer imaging breast imaging epidemiology of cancer cancer management cancer biology breast cancer risk topical bexarotene physical activity respiratory medicine clinical nutrition vascular biology medical internet research women's studies decision science in vitro toxicology cosmetic dermatology cancer letter palliative medicine jama oncology gynecologic oncology clinical evidence cohort studies treatment options fitness measure early detection genetic disorders riskbenefit ratio health disparities medical decision analysis decision aids risk communication patient support cancer risk cancer education cancer literacy drug trials cancer treatment cancer screening clinical decision-making disease management patient management general internal medicine clinical factors physical activity guidelines cancer prevention patients li-fraumeni syndrome education low-numerate women high-risk breast lesions decision support tools patient-provider communication biomarker modulation alternative dosing postmenopausal women premalignant breast conditions

Notable Scholarly Works

Notable Federal Grants

Collaborators

Data From Time-Restricted Eating and Metformin in Invasive Breast Cancer or Dcis: A Randomized, Phase Iib, Presurgical Trial. Preliminary Safety Analysis. (2026)

time-restricted eatingmedicinebreast surgerycancer carepreliminary safety analysisclinical trialsbreast canceroncologyphase iibhealth sciencesbreast oncology

Abstract P2-12-19: A Randomized Phase II Window-Of-Opportunity Trial of Ruxolitinib in Patients With High Risk and Premalignant Breast Conditions. Clinical Cancer Research (2025)

medicinebreast surgerypharmacologycancer carehigh riskpremalignant breast conditionsradiation oncologypharmacotherapytherapeutic targetsclinical trialsbreast canceroncologyabstract p2-12-19breast oncology

Abstract Ps16-09: A Decision Support Intervention to Promote the Use of Preventive Therapy Among Women at High Risk for Invasive Breast Cancer. Clinical Cancer Research (2025)

public healthhigh riskcancer careabstract ps16-09preventive healthcaredecision support interventionbreast canceroncologypreventive medicinecancer screeninggynecologycancer preventionwomen's healthbreast oncology

Supplementary Table 1 From Phase I Dose Escalation Study of Topical Bexarotene in Women at High Risk for Breast Cancer. (2025)

dermatologypharmacologysupplementary table 1high riskpharmacotherapyapplied pharmacologyclinical trialsbreast canceroncologydrug deliverybreast oncology

Abstract Ps07-01: Exemestane and Breast Cancer Prevention: How Low Can We Go? Drug and Biomarker Tissue Levels in a Randomized Presurgical Trial on Exemestane Alternative Dosing Regimen. Cancer Research (2024)

Davide SerranoHarriet JohanssonBjørn-Erik BertelsenGunnar MellgrenParijatham ThomasKatherine CrewNagi B KumarDebora MacisValentina AristarcoAliana Guerrieri GonzagaSara GandiniMauro D’AmicoTania Buttiron WebberIrene Maria BriataStefano SpinaciViviana GalimbertiGiuseppe VialeLana A. VornikEduardo Villar-SanchezPowel BrownBrandy M Heckman-StoddardEva SzaboBernardo BonanniAndrea De Censi

medicinepharmacologycancer researchcancer preventionrandomized presurgical trialoncologybiomarker tissue levelscancer biologyhealth sciences

Alternative Dosing Regimen of Exemestane in a Randomized Presurgical Trial: The Role of Obesity in Biomarker Modulation. npj Breast Cancer (2024)

Harriet JohanssonAliana Guerrieri-GonzagaSara GandiniBjørn-Erik BertelsenDebora MacisDavide SerranoGunnar MellgrenMatteo LazzeroniParijatham S. ThomasKatherine D. CrewNagi B. KumarIrene Maria BriataViviana GalimbertiGiuseppe VialeLana A. VornikValentina AristarcoTania Buttiron WebberStefano SpinaciPowel H. BrownBrandy M. Heckman-StoddardEva SzaboBernardo BonanniAndrea DeCensi

pharmacologyradiation oncologysurgical oncologyobesityrandomized presurgical trialbreast canceroncologybiomarker modulationhealth sciencesbreast oncology

Drug and Biomarker Tissue Levels in a Randomized Presurgical Trial on Exemestane Alternative Schedules. JNCI Journal of the National Cancer Institute (2024)

Davide SerranoHarriet JohanssonBjørn-Erik BertelsenSara GandiniGunnar MellgrenParijatham ThomasKatherine D CrewNagi B KumarDebora MacisValentina AristarcoAliana Guerrieri-GonzagaMatteo LazzeroniMauro D’AmicoTania Buttiron-WebberIrene Maria BriataStefano SpinaciViviana GalimbertiLana A VornikEduardo Villar-SanchezPowel H BrownBrandy M Heckman-StoddardEva SzaboBernardo BonanniAndrea DeCensi

biomarkerspharmacologyexemestane alternative schedulesclinical trialsrandomized presurgical trialbiomarker tissue levelsdrug trials

Abstract P4-06-09: A Phase 1B Study of Neratinib With Thp in Metastatic and Locally Advanced Breast Cancer, and Phase II Study of Thp Followed by Ac in Her2 + Primary Inflammatory Breast Cancer (Ibc), and Neratinib With Taxol Followed by Ac in Hr+/Her2- Ibc. Cancer Research (2023)

advanced breast cancerpharmacologymetastasishr+/her2- ibcradiation oncologycancer researchphase 1bbreast canceroncologyoncogenesmedicinal researchcancer treatmentbreast oncology

A Randomized Presurgical Trial of Alternative Dosing of Exemestane in Postmenopausal Women With Early-Stage Er-Positive Breast Cancer.. Journal of Clinical Oncology (2022)

Andrea De CensiDavide SerranoSara GandiniParijatham S. ThomasKatherine D. CrewNagi B. KumarJ. Jack LeePaolo VeronesiAliana Guerrieri-GonzagaHarriet JohanssonMauro D'AmicoFlavio GuasoneBjorn-Erik ErtelsenGunnar MellgrenIsabelle BedrosianEileen DimondBrandy M. Heckman-StoddardEva SzaboPowel BrownBernardo Bonanni

pharmacologyalternative dosingradiation oncologysurgical oncologyrandomized presurgical trialoncologybreast cancerpostmenopausal women

Phase I Dose Escalation Study of Topical Bexarotene in Women at High Risk for Breast Cancer. Cancer Prevention Research (2022)

in vitro toxicologydermatologypharmacologyhigh risktopical bexarotenecosmetic dermatologybreast canceroncologybreast oncology

1
2
10 / page

Parijatham Thomas

Associate Professor

The University of Texas MD Anderson Cancer Center

Affiliations

Department Of Clinical Cancer Prevention, 1515 Holcombe Blvd. Unit 1360

Department Of Clinical Effectiveness

Division Of Cancer Prevention And Population Sciences

The University of Texas MD Anderson Cancer Center

Parijatham Thomas is currently serving as a Clinical Cancer Prevention, 1515 Holcombe Blvd. Unit 1360 Associate Professor at The University of Texas Md Anderson Cancer Center.

Honors

Create free account to unlock more features

Experiences

Create free account to unlock more features

Education

Create free account to unlock more features

Parijatham Thomas

The University of Texas MD Anderson Cancer Center

Associate Professor

You can click a keyword to filter the displayed items

Notable Scholarly Works

Notable Federal Grants

Collaborators

Data From Time-Restricted Eating and Metformin in Invasive Breast Cancer or Dcis: A Randomized, Phase Iib, Presurgical Trial. Preliminary Safety Analysis. (2026)

time-restricted eatingmedicinebreast surgerycancer carepreliminary safety analysisclinical trialsbreast canceroncologyphase iibhealth sciencesbreast oncology

Abstract P2-12-19: A Randomized Phase II Window-Of-Opportunity Trial of Ruxolitinib in Patients With High Risk and Premalignant Breast Conditions. Clinical Cancer Research (2025)

Abstract Ps16-09: A Decision Support Intervention to Promote the Use of Preventive Therapy Among Women at High Risk for Invasive Breast Cancer. Clinical Cancer Research (2025)

Supplementary Table 1 From Phase I Dose Escalation Study of Topical Bexarotene in Women at High Risk for Breast Cancer. (2025)

dermatologypharmacologysupplementary table 1high riskpharmacotherapyapplied pharmacologyclinical trialsbreast canceroncologydrug deliverybreast oncology

medicinepharmacologycancer researchcancer preventionrandomized presurgical trialoncologybiomarker tissue levelscancer biologyhealth sciences

Alternative Dosing Regimen of Exemestane in a Randomized Presurgical Trial: The Role of Obesity in Biomarker Modulation. npj Breast Cancer (2024)

pharmacologyradiation oncologysurgical oncologyobesityrandomized presurgical trialbreast canceroncologybiomarker modulationhealth sciencesbreast oncology

Drug and Biomarker Tissue Levels in a Randomized Presurgical Trial on Exemestane Alternative Schedules. JNCI Journal of the National Cancer Institute (2024)

biomarkerspharmacologyexemestane alternative schedulesclinical trialsrandomized presurgical trialbiomarker tissue levelsdrug trials

advanced breast cancerpharmacologymetastasishr+/her2- ibcradiation oncologycancer researchphase 1bbreast canceroncologyoncogenesmedicinal researchcancer treatmentbreast oncology

A Randomized Presurgical Trial of Alternative Dosing of Exemestane in Postmenopausal Women With Early-Stage Er-Positive Breast Cancer.. Journal of Clinical Oncology (2022)

pharmacologyalternative dosingradiation oncologysurgical oncologyrandomized presurgical trialoncologybreast cancerpostmenopausal women

Phase I Dose Escalation Study of Topical Bexarotene in Women at High Risk for Breast Cancer. Cancer Prevention Research (2022)

in vitro toxicologydermatologypharmacologyhigh risktopical bexarotenecosmetic dermatologybreast canceroncologybreast oncology

1
2
10 / page